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A B S T R A C T
Non-steroidal anti-inflammatory drugs (NSAIDs) have prohypertensive effects and blunt the effects of many anti-
hypertensives. The mechanism of this interaction is still not understood enough. The objective of this investigation was
to determine the level of prohypertensive effects of two NSAIDs (ibuprofen, piroxicam) and paracetamol, co-prescribed
with two antihypertensive drugs (lisinopril + hydrochlorothiazide, amlodipine), and to improve the understanding of
this interaction. A prospective clinical trial, conducted in a Croatian family practice, included 110 already treated hyper-
tensive patients, aged 56–85 years; 50 control patients and 60 patients who were also taking NSAIDs for osteoarthritis
treatment. The antihypertensive regimens remained the same during this study, while NSAIDs and paracetamol were
crossed-over in three monthly periods. Blood pressure, body weight, serum creatinine, potassium, sodium, diuresis and
24 h urinary sodium excretion were followed-up. In the lisinopril/hydrochlorothiazide subgroup, both ibuprofen and
piroxicam elevated mean arterial pressure by 8.9–9.5% (p<0.001). Body weight increased significantly in the lisinopril/
hydrochlorothiazide + piroxicam subgroup only, while creatinine, urinary output and electrolyte values did not change
appreciably in any of the subgroups. NSAID’s prohypertensive effects seem to be mostly due to vasoconstriction and, to a
minor degree, to volume expansion, since no marked changes in body weight, urinary output, serum creatinine or se-
rum/urinary electrolyte profile were observed.
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Introduction
Analgesic and anti-inflammatory properties of non-
-steroidal anti-inflammatory drugs (NSAIDs) derive
from synthesis inhibition of several prostaglandins (ara-
chidonic acid derivatives, eicosanoid group), mediated by
cyclooxygenase (COX)1. Prostaglandins have various, of-
ten opposite, effects on different organs, e.g. a decrease
in hydrochloric acid and pepsin secretion, an increase in
the amount of mucus in the digestive system, a rise in
glomerular filtration rate, a reduction in sodium, chlo-
ride and water reabsorption in the kidneys, a respiratory
smooth muscle relaxation or an increase in afferent pain
threshold1. Complex interactions between vasodilatory
(e.g. PGE) and vasoconstrictive (e.g. TxA2) prostanoids
have been described, as well as interactions with other
endothelial mediators like nitric oxide or endothelin2.
There are different COX isoforms, the most promi-
nent being constitutive
(COX-1) and inducible (COX-2) ones. COX-1 is perma-
nently active in many tissues, regulating normal cellular
activity (gastric mucosa, vascular endothelium, kidney
tubules, platelets). COX-2 is constantly active in brain,
kidneys and blood vessels; in the rest of the body, it is pri-
marily induced by inflammation1.
The NSAID’s influence on arterial pressure has been
widely investigated3–20.
Prostaglandin synthesis inhibition can lead to signifi-
cant interaction between NSAIDs and various antihyper-
tensive drugs, especially if these agents are eicosanoid-
-dependent. It seems that ACE inhibitors, diuretics and
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-blockers (and, to a lesser degree, angiotensin II recep-
tor blockers) are more affected by this interaction, i.e.
more susceptible to impaired control of elevated blood
pressure (BP), whereas calcium channel blockers are
more resistant3,4. The reasons why some antihyperten-
sives behave differently in this respect are still unclear.
For example, NSAIDs reduce natriuretic effect of diuret-
ics (PGE dependent, especially PGE2), and suppress di-
uretic-induced renin activation. ACE inhibitors’ anti-
hypertensive effect is probably weakened by NSAIDs’
diminution in bradykinin secretion and subsequent re-
lease of vasodilatory and/or natriuretic compounds (e.g.
nitric oxide). Possible mechanisms include different de-
grees of COX isoenzyme inhibition, different concentra-
tions in critical biophase, or some side-effects (e.g. on an-
giotensin II or endothelin levels, or their receptor sensi-
tivity)3.
The objective of this study was to determine the
prohypertensive effects of two NSAIDs (ibuprofen, piro-
xicam) and paracetamol when used in combination with
lisinopril/hydrochlorothiazide or amlodipine, and to re-
fine the understanding of this interaction (predominant
influence on kidney function or on vascular resistance).
Therefore, besides BP alterations this trial was designed
to assess the changes in body weight, serum creatinine,
sodium and potassium, diuresis, and 24 h urinary sodium
excretion.
Materials and Methods
After signing informed consent, approved by the Split
University School of Medicine Ethical Committee, 110
already treated hypertensive patients, aged above 55
years, were involved in this prospective clinical trial
(ClinicalTrials.gov #NCT00631514)3. The initial results
concerning NSAID effects on arterial blood pressure in a
group of 88 patients have already been published3; here
we present the data about body weight changes, serum
creatinine, potassium and sodium values, urine output,
sodium values in 24 h urine and mean arterial pressure
for 110 examinees (final data), with some considerations
of the mechanism of this interaction.
The control group consisted of 50 hypertensives trea-
ted for elevated blood pressure only, while the interven-
tion group consisted of 60 hypertensives who were also
taking NSAIDs for knee or hip osteoarthritis treatment.
During this 3-month cross-over study, the interaction be-
tween antihypertensives (amlodipine or lisinopril/hydro-
chlorothiazide fixed combination) and analgesics (ibu-
profen, paracetamol and piroxicam) was investigated.
The inclusion criteria for enrollment in the study
were: either gender, age 55 or older, diastolic blood pres-
sure of 90–100 mm Hg, absence of cardiac failure and se-
rum creatinine below 150 mmol/l. The intervention group
had additional inclusion criteria: concomitant knee or
hip osteoarthritis requiring NSAIDs treatment. The ex-
clusion criteria were: worsening of hypertension (dia-
stolic blood pressure exceeding 110 mm Hg), myocardial
infarction, necessity of additional antihypertensive treat-
ment, failure to take the studied drugs for more than
three days, considerable worsening of the joint condition
after the NSAIDs exclusion. The examinees were not al-
lowed to take other drugs that could alter renal function.
Since all of them were already hypertensive, and previ-
ously instructed about dietary habits, no additional salt
intake restrictions were recommended.
Following clinical work-up and discontinuation of
NSAIDs for at least 3 days, the run-in period lasted 3–7
days. Wash-out was relatively short, since we could not
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TABLE 1
BASELINE CHARACTERISTICS OF THE EXAMINEES
Study group Control Intervention
Parameter L/H AM L/H±IB L/H±PX AM±IB AM±PX p
Randomized (n) 25 25 15 15 15 15
Male/female (n) 15/10 13/12 7/8 5/10 5/10 4/11 0.653
Age (years; X±SD) 68.1±6.2 69.7±8.2 70.57.2 69.77.4 69.56.7 69.58.6 0.900
Weight (kg; X±SD) 81.811.0 80.5±15.1 84.515.7 79.613.4 80.112.3 85.513.8 0.766
BMI (kg/m2; X±SD) 28.33.3 27.4±4.2 29.14.0 28.64.3 29.34.7 30.13.0 0.399
Systolic BP (mm Hg) 151.513.0 149.7±9.0 147.510.6 149.710.1 150.59.2 154.19.6 0.632
Diastolic BP (mm Hg) 88.76.4 86.8±5.7 85.76.8 86.75.7 84.08.8 86.98.6 0.469
Plasma creatinine (mmol/L) 91.818.2 97.6±23.3 91.5±25.3 92.3±24.1 86.9±18.4 78.0±5.9 0.342
Plasma sodium (mmol/L) 142.0±2.6 141.5±3.0 141.8±2.3 140.9±2.4 141.5±1.6 140.4±2.6 0.672
Urinary output (mL/24h) 1888.1730.0 1696.0±548.9 1492.9828.4 1737.5406.5 2092.0760.6 1331.3407.9 0.093
Urinary sodium excretion
(mmol/24h) 199.484.0 168.7±76.7 182.691.9 171.077.8 230.4100.8 175.956.0
0.562
AM – amlodipine, BMI – body mass index, BP – blood pressure, IB – ibuprofen; L/H – lisinopril/hydrochlorothiazide,
MAP – mean arterial pressure, PX – piroxicam, ±SD – Means ± standard deviations of the data
afford any longer period because of expected non-compli-
ance (the patients would take some »pain-killers« any-
way). The intervention group was randomized (sealed
envelopes) in two subgroups; one taking ibuprofen 400–
600 mg three times a day for 1 month, then paracetamol
1000 mg 2–3 times a day for another month, and finally
taking the same ibuprofen dose for the 3rd month, while
the other subgroup was taking piroxicam 10–20 mg once
a day for 1 month, followed by paracetamol 1000 mg 2–3
times a day for another month, and resuming piroxicam
in the 3rd month. All the examinees continued their
antihypertensive medications throughout the study: li-
sinopril/hydrochlorothiazide 10/6.25–20/12.5 mg once a
day or amlodipine 5–10 mg once a day. Individual drug
dosage was titrated before the formal study and during
the first study period if deemed necessary by the pre-
scribing physician.
At the inception of this trial a clinical examination
was performed, as well as a set of biochemical measure-
ments (serum creatinine, potassium, sodium and 24-h
urinary sodium), using an »AU 600 Olympus« chemistry
analyzer. Body height and weight were measured by using
a physician decimal scale with a sliding counterweight
and a height rod »Detecto 2391« (USA). Dominant arm
BP was measured with a mercury sphygmomanometer,
taking the mean of the last two of three consecutive read-
ings in the supine, sitting and standing positions, and
30-min ambulatory BP monitoring was performed with
»VSM Medech Ltd. Model BPM-100« (Vancouver, Can-
ada) automated recorder3.
The same measurements were repeated after each
month of the study. Results were compared between and
within the study groups. Here we present the blood pres-
sure recordings in the seated position as mean arterial
pressure (MAP) changes, as well as body weight, serum
creatinine, potassium and sodium levels, 24 h urinary
output and sodium excretion. The obtained data was tab-
ulated, presented as means and standard deviations (±SD),
and statistically evaluated using the software package
»SPSS 11.5«, Chicago, Illinois. Significance of the ob-
served differences was assessed using the paired and un-
paired t-test and the analysis of variance (ANOVA). A p
value of <0.05 was regarded as significant; the p values
were corrected for multiple testing with the Bonferroni
adjustment.
Results
A total of 110 examinees, 49 males (44.5%) and 61 fe-
males (55.5%), were enrolled in the study. The interven-
tion group included 60 (54.6%) and the control group 50
(45.4%) patients. The intervention group patients were
allocated in 4 equal subgroups: 15 were taking lisinopril/
hydrochlorothiazide with ibuprofen (L/H±IB), and 15
with piroxicam (L/H±PX); 15 were taking amlodipine
with ibuprofen (AM±IB), and 15 with piroxicam (AM±
PX). The control group was divided in two subgroups: 25
examinees were taking lisinopril/hydrochlorothiazide
and 25 amlodipine only (Table 1). There were no signifi-
cant differences between the intervention and control
subgroups concerning age (p=0.90), gender (p=0.653) or
prescribed drugs (p=0.338). The average daily dosage
was 18.0±4.5/11.3±2.8 mg for lisinopril/hydrochlorothia-
zide, 6.9±2.4 mg for amlodipine, 1154±348 mg for ibu-
profen, 16.9±4.8 mg for piroxicam, and 2490±429 mg for
paracetamol; the individual doses were held constant
during the study phases.
Mean arterial pressure (MAP) in the L/H±IB sub-
group changed significantly during this study (Table 2):
the introduction of ibuprofen brought about a marked in-
crease by 8.9% (9.5 mm Hg; p<0.001); its withdrawal
during the paracetamol phase resulted in a decrease al-
most to the baseline values, and reintroduction of ibu-
profen was followed by a 7.5% increase in MAP (p=
0.003). In the L/H±PX subgroup similar, even more pro-
nounced changes were registered: during the piroxicam
phase MAP increased from baseline by 9.5% (10.2 mm
Hg; p<0.001), during paracetamol it returned to mere
0.6% above baseline (p>0.5), and when piroxicam was re-
introduced MAP increased again by 7.9% (p<0.001). In
the AM±IB and AM±PX subgroups the between-phase
MAP deviations were minor and insignificant.
Body weight (Table 3, Figure 1) increased signifi-
cantly in L/H±PX subgroup only (from 79.6±13.4 kg to
81.5±14.0 kg or +1.9 kg; p=0.028). Plasma creatinine
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TABLE 2
MEAN ARTERIAL PRESSURE CHANGES VS. BASELINE DURING
IBUPROFEN, PIROXICAM OR PARACETAMOL
Antihypertensive L/H AM
NSAID Absolute (and percentual) changes
IB (mm Hg) +9.5 (8.9%)*** +0.5 (0.5%)
PX (mm Hg) +10.2 (9.5%)*** +0.5 (0.5%)
PA (mm Hg) +1.4 (1.3%) +0.2 (0.2%)
***p<0.001, AM – amlodipine, IB – ibuprofen, L/H – lisinopril/























Fig. 1. Body weight changes during the study periods (error bars
showing standard deviations of the data). AM – amlodipine, IB –
ibuprofen, L/H – lisinopril/hydrochlorothiazide, PX – piroxicam.
values (Table 3) did not change significantly in any of the
groups, though they displayed an increasing trend. Pla-
sma potassium concentrations (Table 3), displayed an in-
creasing trend (e.g. +5.3% in the L/H±PX subgroup), but
the changes were insignificant in all of the groups (p>
0.15). Plasma sodium concentrations in both lisinopril/
hydrochlorothiazide subgroups remained the same, whi-
le insignificant changes occurred in the amlodipine sub-
groups (Table 3). Sodium excretion in 24 h urine was
4.9% higher in the L/H±IB subgroup compared to the
baseline (Table 3), 5.1% higher in the L/H±PX subgroup
and lower in both of the amlodipine subgroups (1.9% in
AM±IB and 8.6% in AM±PX). These changes were not
statistically significant either (p>0.25). The volume of 24
h urine in the intervention group did not change signifi-
cantly during this study. Urinary output was reduced by
10.8% in the L/H±IB subgroup, 8.8% in the L/H±PX sub-
group and 21.1% in the AM±IB subgroup, but increased
by 3.5% in the AM±PX subgroup (Table 3). All of these
changes were insignificant (p>0.25). However, a signifi-
cant increase in diuresis was registered in the control
amlodipine group after the first phase (from 1696.0±
548.9 mL to 2534.3±693.6 mL or +838.3 mL; p=0.003).
There were no drop-outs from this study. Some minor
and expected side-effects were noted in the amlodipine
group only: 9 examinees had ankle edema (4 of them in
the intervention group and 5 in the control group), but
none withdrew from the study. NSAID-related side-ef-
fects were noted in 3 examinees in the piroxicam sub-
groups (mild gastrointestinal symptoms).
Discussion
Our trial has confirmed that ibuprofen and piroxicam
significantly reduce the antihypertensive effects of lisi-
nopril/hydrochlorothiazide combination, while paraceta-
mol was almost inert in this respect. On the other hand,
adding ibuprofen or piroxicam does not influence amlo-
dipine’s antihypertensive activity3.
Body weight during NSAID intake did not change ap-
preciably, except in the L/H±PX subgroup (+1.9 kg).
Other investigators have obtained discordant results:
some showed a significant increase, while others did
not5–10. Klassen et al. have reported a significant increase
in body weight during naproxen intake7, while Radack et
al. did not observe body weight gain with either ibupro-
fen or paracetamol10. Such increment, reflecting fluid re-
tention and plasma volume expansion, is usually short-
-term, happens during the first week of NSAID therapy
and usually does not surpass 2 kg11,12. Creatinine levels
and urine volume did not change appreciably in this
study, which is congruent to other reports5,6. According
to a meta-analysis done by Johnson et al.13, sodium and
fluid retention does not seem to be the leading cause of
prohypertensive NSAID activity, since body weight and
sodium values did not change with NSAIDs and diuretics
were not superior to other antihypertensives. Although
our results support that point of view, the prohyper-
tensive mechanisms of NSAIDs are still unresolved.
Most published trials were investigating pure NSAIDs
– ACE inhibitors interaction while, in this study, the
examinees were taking a fixed combination of an ACE in-
hibitor, lisinopril, and a diuretic, hydrochlorothiazide5,6,8,14.
That combination in concert with NSAIDs did not lead to
significant serum potassium elevation, except in the L/H±
PX subgroup. In another study, indomethacin increased
serum potassium level among hypertensive subjects trea-
ted with enalapril (more) and felodipine (less), while a
subsequent investigation by the same authors has not
found a significant change (indomethacin with amlodi-
pine or enalapril)5,6.
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TABLE 3
BODY WEIGHT, PLASMA CREATININE, POTASSIUM, SODIUM, DIURESIS, AND 24 H URINARY SODIUM ALTERATIONS VS. BASELINE
Study group
Control Intervention
L/H AM L/H+IB L/H+PA L/H+PX AM+IB AM+PA AM+PX





























































































**p=0.028, **p=0.003, AM – amlodipine, IB – ibuprofen, L/H – lisinopril/hydrochlorothiazide, PA – paracetamol, PX – piroxicam
Sodium values did not change significantly in our
trial, but there was a slight difference between the inter-
vention and the control amlodipine group. The baseline
natriuria was quite high, presumably due to inadequate
diet (too high salt intake; around 12 g/day or 200 mmol
Na/day). In either lisinopril/hydrochlorothiazide or amlo-
dipine subgroups, the addition or exclusion of NSAIDs
did not bring about a statistically significant change in
the 24h urine sodium excretion. In another study15,
NSAIDs did not decrease natriuresis in examinees trea-
ted with lisinopril and hydrochlorothiazide. In the Polo-
nia et al. paper8, indomethacin caused a significant drop
in natriuria among hypertensives treated with enalapril,
but also among those receiving nifedipine. In the study,
performed by Krekels et al., a daily dose of 20 mg nitren-
dipine caused a significant natriuretic effect independent
of it’s hemodynamic activity16.
Prohypertensive effects of NSAIDs in their interac-
tion with antihypertensives depend on the relative role
the prostaglandins play in hypotensive activity of each
drug, i.e. on the importance of prostaglandin inhibition
in a particular blood pressure-lowering effect13. Decrea-
sed synthesis of natriuretic prostaglandins (PGE2) en-
hances sodium retention by lowering saluresis. Thus,
during the NSAID phases in our experiment, there was
less natriuresis expected in lisinopril/hydrochlorothia-
zide than in amlodipine subgroups. However, no signifi-
cant changes in 24 h urinary sodium excretion were ob-
served.
Blood pressure increase in lisinopril/hydrochlorothia-
zide intervention subgroups was not accompanied by
body weight increase and/or decrease in urinary sodium
excretion, suggesting that vasoconstriction, instead of
volume expansion, is the dominant mechanism of blood
pressure increase in hypertensive patients taking con-
comitant NSAIDs. Inhibition of vasodilatory prostaglandin
synthesis is apparently the main cause of prohyperten-
sive NSAID activity; prostacyclin is a strong vasodilator
and abating its synthesis increases peripheral resistance.
In addition, NSAIDs reduce endothelial emission of ni-
tric oxide (NO) and increase renal endothelin synthesis
(ET-1), which is a highly potent vasoconstrictor. ET-1
does not only increase peripheral vascular resistance but
stimulates sodium and water retention as well17. We
found that fluid retention was less important than vaso-
constriction, but we did not perform measurements of
ET-1, renin or angiotensin II. A correlation between
plasma ET-1 and NO concentrations and arterial pres-
sure has been found in diabetic patients receiving ACE
inhibitors18. More pronounced hypertensive effect of
NSAIDs in diabetic nephropathy could be explained with
higher ET-1 levels due to earlier endothelial activation,
even before the onset of microalbuminuria18. ET-1 recep-
tors in endothelial cells are connected to voltage calcium
channels by G proteins19. That might explain why cal-
cium antagonists ameliorate endothelin induced vaso-
constriction; in addition to calcium channels, they block
ET-1 receptors as well.
COX-2 is involved in water and electrolyte homeosta-
sis, while COX-1 is mostly active in vascular endothe-
lium1. Prostaglandins mediated by COX-1 and COX-2
seem to have opposite hemodynamic effects. COX-2 inhi-
bition enhances and prolongs the pressor effect of angio-
tensin II, whereas COX-1 inhibition works the opposite
way. Several NSAIDs have been shown to inhibit COX-2
more than COX-120. According to a report, COX-1/COX-2
inhibition ratio was 0.12 for ketoprofen, 0.32 for ASA,
0.59 for ibuprofen, 1.27 for piroxicam and 7.93 for eto-
dolac21. In our study, piroxicam was more prohyperten-
sive than ibuprofen, which may be explained with this se-
lectivity difference. Paracetamol had little effect on blood
pressure control, presumably because its minor effect on
peripheral prostaglandin synthesis22.
There are some limitations of this study. It was not
double blind but open, with the prescriber physician un-
aware of the results and the assessor physician unaware
of the prescribed drugs. Because of ethical reasons (se-
verity of osteoarthritis), a placebo group was not in-
cluded. Instead, the examinees were given paracetamol
during the wash-out interval between two NSAID peri-
ods (which did not worsen the blood pressure control and
proved to be comparable to placebo).
A dose-response curve can not be extrapolated from
this study either. Since the patients were titrated to the
best antihypertensive and analgesic effect, it may be as-
sumed that the doses of drugs used were individually
equipotent and comparable to those prescribed in clinical
practice.
The number of suitable patients willing to participate
(110 out of possible 223 or 49.3%) and the relatively
small sample size limits the power to prove possibly rele-
vant differences between ibuprofen and piroxicam con-
cerning blood pressure control. Low number of diabetic
and renal patients prevented the assessment of co-mor-
bidity role in these interactions. Hypertensive patients
with plasma creatinine levels above 150 mmol/L were not
included in this study and our results cannot be extrapo-
lated to patients with renal failure.
On the other hand, the study was prospective, ran-
domized, controlled, with parallel and cross-over com-
parison, performed in real conditions of a busy family
practice.
The clinical relevance of its results lies in the individ-
uation of best tolerated combinations of antihyperten-
sive and antirheumatic drugs for hypertensive persons
with rheumatic deseases.
Conclusion
This study confirmed the unfavorable interaction be-
tween some antihypertensives and NSAIDs. Much better
hypertension control was achieved while taking parace-
tamol instead of ibuprofen or piroxicam. Reintroduction
of one of those NSAIDs was followed by a significant
increasse in blood pressure. Since body weight, serum
creatinine, potassium, sodium, urinary output and uri-
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nary sodium excretion did not change noticeably during
the trial, it seems that NSAID’s untoward effects on hy-
pertension control are mainly due to vasoconstriction
and much less to volume expansion.
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PROHIPERTENZIVNO DJELOVANJE NESTEROIDNIH ANTIREUMATIKA JE PRETE@NO
UZROKOVANO VAZOKONSTRIKCIJOM
S A @ E T A K
Nesteroidni antireumatici (NSAR) pokazuju prohipertenzivna svojstva i smanjuju u~inke mnogih antihipertenziva.
Mehanizam ovih interakcija jo{ uvijek nije dovoljno obja{njen. Cilj ovog istra`ivanja bio je: odrediti razinu prohiper-
tenzivnog djelovanja dva NSAR-a (ibuprofen, piroksikam) i paracetamol, uzimana istodobno s dva antihipertenziva
(kombinacija lizinopril/hidroklorotiazida i amlodipin) i pridonijeti razumijevanju ove interakcije. U prospektivno ispi-
tivanje provedeno u ordinaciji obiteljske medicine bilo je uklju~eno 110 lije~enih hipertoni~ara u dobi od 56–85 godina;
50 u kontrolnu i 60 u interventnu skupinu (uzimali i NSAR zbog artroze). Antihipertenzivna terapija nije se mijenjala
tijekom lije~enja, dok je uzimanje NSAR nasumi~no podijeljeno u 3 jednomjese~na razdoblja: faza I – puna doza pro-
pisanog lijeka, faza II – bez NSAR (daje se paracetamol), faza III – ponovno isti antireumatik, u istoj dozi. Nakon svakog
jednomjese~nog razdoblja mjeren je arterijski tlak, tjelesna masa, vrijednosti kreatinina, kalija i natrija u plazmi, diu-
reza i vrijednosti natrija u 24 h urinu. U lizinopril/hidroklorotiazid podskupini kako ibuprofen tako i piroksikam podigli
su srednji arterijski tlak za 8,9–9,5% (<0,001). Zna~ajan porast tjelesne mase na|en je samo u lizinopril/hidrokloro-
tiazid + piroksimam podskupini. Vrijednosti kreatinina, kalija, natrija, diureze i natrija u 24 h urinu nisu se zna~ajno
mijenjale. Budu}i da nisu opa`ene osjetne promjene tjelesne mase, prometa vode ni elektrolita, mehanizam prohiper-
tenzivnog djelovanja NSAR je, ~ini se, prete`no vazokonstrikcijski.
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